Femasys (NASDAQ:FEMY) Given New $10.00 Price Target at Maxim Group

Femasys (NASDAQ:FEMY) had its price objective decreased by Maxim Group to $10.00 in a research note published on Friday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Other analysts have also recently issued reports about the stock. Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Wall Street Zen raised Femasys to a “hold” rating in a research note on Saturday, June 13th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.67.

Femasys Stock Performance

Shares of NASDAQ:FEMY opened at $2.29 on Friday. The stock has a market capitalization of $6.92 million, a price-to-earnings ratio of -0.42 and a beta of -2.08. The business’s fifty day moving average price is $3.59 and its two-hundred day moving average price is $7.31. Femasys has a fifty-two week low of $2.19 and a fifty-two week high of $22.20. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.91 and a quick ratio of 1.98.

Femasys (NASDAQ:FEMY) last posted its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.02). The firm had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.73 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.

Insider Activity

In related news, CEO Kathy Lee-Sepsick acquired 15,625 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $3.20 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief executive officer directly owned 15,625 shares of the company’s stock, valued at $50,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Dov Elefant acquired 15,625 shares of the business’s stock in a transaction on Friday, August 7th. The shares were bought at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief financial officer directly owned 15,625 shares of the company’s stock, valued at approximately $50,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 38,750 shares of company stock worth $124,000 over the last three months. Insiders own 7.75% of the company’s stock.

Institutional Investors Weigh In On Femasys

A number of hedge funds and other institutional investors have recently made changes to their positions in FEMY. Jane Street Group LLC acquired a new position in Femasys during the second quarter valued at approximately $82,000. Osaic Holdings Inc. bought a new position in Femasys in the second quarter valued at about $45,000. Geode Capital Management LLC grew its stake in shares of Femasys by 50.8% during the fourth quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock worth $224,000 after buying an additional 131,052 shares during the last quarter. Kovack Advisors Inc. acquired a new position in shares of Femasys during the fourth quarter worth $27,000. Finally, Banco BTG Pactual S.A. bought a new stake in Femasys during the 4th quarter worth $88,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.